{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:16:02Z","timestamp":1794377762900,"version":"4.9.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,6,20]]},"DOI":"10.1038\/s41416-026-03398-x","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:01:56Z","timestamp":1775556116000},"page":"1744-1753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I\/II trial"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1556-0820","authenticated-orcid":false,"given":"Maarten A.","family":"Huismans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eelke H.","family":"Gort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa T.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin M.","family":"Guven Mese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena M.","family":"Klein Wolterink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon N. G. J. A.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd G.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-5991","authenticated-orcid":false,"given":"Filip Y. F. L.","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lot A.","family":"Devriese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk M. W.","family":"Verheul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans L.","family":"Opdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-1978","authenticated-orcid":false,"given":"Miriam","family":"Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde H.","family":"Nienhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen A.","family":"Crommelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4189-5213","authenticated-orcid":false,"given":"Hugo J. G.","family":"Snippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1398-8970","authenticated-orcid":false,"given":"Jeanine M. L.","family":"Roodhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"3398_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/gastro\/goaa022","volume":"8","author":"Z-N Li","year":"2020","unstructured":"Li Z-N, Zhao L, Yu L-F, Wei M-J. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterol Rep. 2020;8:192\u2013205.","journal-title":"Gastroenterol Rep"},{"key":"3398_CR2","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014;13:828\u201351.","journal-title":"Nat Rev Drug Discov"},{"key":"3398_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548\u201351.","journal-title":"Nature"},{"key":"3398_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41421-021-00368-w","volume":"8","author":"Z Mao","year":"2022","unstructured":"Mao Z, Xiao H, Shen P, Yang Y, Xue J, Yang Y, et al. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discov. 2022;8:5.","journal-title":"Cell Discov"},{"key":"3398_CR5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","volume":"29","author":"J Liu","year":"2022","unstructured":"Liu J, Kang R, Tang D. The KRAS-G12C inhibitor: activity and resistance. Cancer Gene Ther. 2022;29:875\u20138.","journal-title":"Cancer Gene Ther"},{"key":"3398_CR6","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.molmed.2007.10.002","volume":"13","author":"NV Sergina","year":"2007","unstructured":"Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007;13:527\u201334.","journal-title":"Trends Mol Med"},{"key":"3398_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","volume":"15","author":"MB Ryan","year":"2018","unstructured":"Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol. 2018;15:709\u201320.","journal-title":"Nat Rev Clin Oncol"},{"key":"3398_CR8","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.aav4474","volume":"366","author":"M Russo","year":"2019","unstructured":"Russo M, Crisafulli G, Sogari A, Reilly NM, Arena S, Lamba S, et al. Adaptive mutability of colorectal cancers in response to targeted therapies. Science. 2019;366:1473\u201380.","journal-title":"Science"},{"key":"3398_CR9","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.18.02459","volume":"37","author":"E Van Cutsem","year":"2019","unstructured":"Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle P-J, Elez E, et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the Phase III BEACON colorectal cancer study. J Clin Oncol. 2019;37:1460\u20139.","journal-title":"J Clin Oncol"},{"key":"3398_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.celrep.2014.02.045","volume":"7","author":"C Sun","year":"2014","unstructured":"Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 2014;7:86\u201393.","journal-title":"Cell Rep"},{"key":"3398_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, I Ou S-H, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;388:44\u201354.","journal-title":"N Engl J Med"},{"key":"3398_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/onco.13631","volume":"26","author":"EMJ Van Brummelen","year":"2021","unstructured":"Van Brummelen EMJ, Huijberts S, van Herpen C, Desar I, Opdam F, van Geel R, et al. Phase I study of afatinib and selumetinib in patients with KRAS-mutated colorectal, non-small cell lung, and pancreatic cancer. Oncologist. 2021;26:290\u2013e545.","journal-title":"Oncologist"},{"key":"3398_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00280-020-04066-4","volume":"85","author":"SCFA Huijberts","year":"2020","unstructured":"Huijberts SCFA, Van Geel RMJM, Van Brummelen EMJ, Opdam FL, Marchetti S, et al. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. Cancer Chemother Pharmacol. 2020;85:917\u201330.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3398_CR14","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/s41416-020-0776-z","volume":"122","author":"RMJM Van Geel","year":"2020","unstructured":"Van Geel RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, De Vos FYFL, Lolkema MPJK, et al. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1\/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. Br J Cancer. 2020;122:1166\u201374.","journal-title":"Br J Cancer"},{"key":"3398_CR15","doi-asserted-by":"crossref","unstructured":"Verissimo CS, Overmeer RM, Ponsioen B, Drost J, Mertens S, Verlaan-Klink I, et al. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. eLife. 2016;5:e18489.","DOI":"10.7554\/eLife.18489"},{"key":"3398_CR16","doi-asserted-by":"publisher","first-page":"112324","DOI":"10.1016\/j.celrep.2023.112324","volume":"42","author":"S Mertens","year":"2023","unstructured":"Mertens S, Huismans MA, Verissimo CS, Ponsioen B, Overmeer R, Proost N, et al. Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer. Cell Rep. 2023;42:112324.","journal-title":"Cell Rep"},{"key":"3398_CR17","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1200\/JCO.2005.16.584","volume":"23","author":"HA Burris","year":"2005","unstructured":"Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O\u2019Neil B, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23:5305\u201313.","journal-title":"J Clin Oncol"},{"key":"3398_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2171-y","volume":"16","author":"C Thallinger","year":"2016","unstructured":"Thallinger C, Lang I, Kuhar CG, Bartsch R, Singer CF, Petruzelka L, et al. Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2\/neu- positive advanced breast cancer: results of the CECOG LaVie trial. BMC Cancer. 2016;16:121.","journal-title":"BMC Cancer"},{"key":"3398_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/bjc.2017.10","volume":"116","author":"JC Bendell","year":"2017","unstructured":"Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, et al. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1\/2 inhibitor. Br J Cancer. 2017;116:575\u201383.","journal-title":"Br J Cancer"},{"key":"3398_CR20","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","volume":"21","author":"W Xia","year":"2002","unstructured":"Xia W, Mullin RJ, Keith BR, Liu L-H, Ma H, Rusnak DW, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/erbB2 and downstream Erk1\/2 and AKT pathways. Oncogene. 2002;21:6255\u201363.","journal-title":"Oncogene"},{"key":"3398_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"3398_CR22","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.annonc.2020.05.012","volume":"31","author":"CH Barcenas","year":"2020","unstructured":"Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol. 2020;31:1223\u201330.","journal-title":"Ann Oncol"},{"key":"3398_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/FTD.0000000000000349","volume":"38","author":"M Herbrink","year":"2016","unstructured":"Herbrink M, de Vries N, Rosing H, Huitema ADR, Nuijen B, Schellens JHM, et al. Quantification of 11 therapeutic kinase inhibitors in human plasma for therapeutic drug monitoring using liquid chromatography coupled with tandem mass spectrometry. Ther Drug Monit. 2016;38:649\u201356.","journal-title":"Ther Drug Monit"},{"key":"3398_CR24","doi-asserted-by":"publisher","first-page":"114772","DOI":"10.1016\/j.jpba.2022.114772","volume":"215","author":"LT van der Heijden","year":"2022","unstructured":"van der Heijden LT, Gebretensae A, Thijssen B, van Andel L, Nijstad AL, Wang Y, et al. A highly sensitive bioanalytical method for the quantification of vinblastine, vincristine, vinorelbine and 4-O-deacetylvinorelbine in human plasma using LC-MS\/MS. J Pharm Biomed Anal. 2022;215:114772.","journal-title":"J Pharm Biomed Anal"},{"key":"3398_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161:933\u201345.","journal-title":"Cell"},{"key":"3398_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","volume":"575","author":"P Priestley","year":"2019","unstructured":"Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019;575:210\u20136.","journal-title":"Nature"},{"key":"3398_CR27","unstructured":"Hartwig Medical Foundation \u00b7 GitHub [Internet]. [cited 2024 26]. Available from: https:\/\/github.com\/hartwigmedical."},{"key":"3398_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.humpath.2016.03.001","volume":"54","author":"S Holck","year":"2016","unstructured":"Holck S, Bonde J, Pedersen H, Petersen AA, Chaube A, Nielsen HJ, et al. Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations. Hum Pathol. 2016;54:37\u201346.","journal-title":"Hum Pathol"},{"key":"3398_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/bjc.2011.591","volume":"106","author":"E Brain","year":"2012","unstructured":"Brain E, Isambert N, Dalenc F, Di\u00e9ras V, Bonneterre J, Rezai K, et al. Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2. Br J Cancer. 2012;106:673\u20137.","journal-title":"Br J Cancer"},{"key":"3398_CR30","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/annonc\/mdr328","volume":"23","author":"HK Chew","year":"2012","unstructured":"Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, et al. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol. 2012;23:1023\u20139.","journal-title":"Ann Oncol"},{"key":"3398_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-3-108","volume":"3","author":"HK Chew","year":"2014","unstructured":"Chew HK, Schwartzberg L, Badarinath S, Rubin P, Shumaker G, Daugherty J, et al. Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer. Springerplus. 2014;3:108.","journal-title":"Springerplus"},{"key":"3398_CR32","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381:1632\u201343.","journal-title":"N Engl J Med"},{"key":"3398_CR33","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1007\/s10637-011-9789-z","volume":"30","author":"T Takahashi","year":"2012","unstructured":"Takahashi T, Boku N, Murakami H, Naito T, Tsuya A, Nakamura Y, et al. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Investig New Drugs. 2012;30:2352\u201363.","journal-title":"Investig New Drugs"},{"key":"3398_CR34","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1200\/JCO.2010.33.9432","volume":"29","author":"BH O\u2019Neil","year":"2011","unstructured":"O\u2019Neil BH, Goff LW, Kauh JSW, Strosberg JR, Bekaii-Saab TS, Lee R-M, et al. Phase II study of the mitogen-activated protein kinase 1\/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011;29:2350\u20136.","journal-title":"J Clin Oncol"},{"key":"3398_CR35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s10637-013-9988-x","volume":"32","author":"P LoRusso","year":"2014","unstructured":"LoRusso P, Venkatakrishnan K, Chiorean EG, Noe D, Wu J-T, Sankoh S, et al. Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. Investig New Drugs. 2014;32:160\u201370.","journal-title":"Investig New Drugs"},{"key":"3398_CR36","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","volume":"13","author":"JR Infante","year":"2012","unstructured":"Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:773\u201381.","journal-title":"Lancet Oncol"},{"key":"3398_CR37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10637-012-9890-y","volume":"31","author":"J Marshall","year":"2013","unstructured":"Marshall J, Hwang J, Eskens FALM, Burger H, Malik S, Uttenreuther-Fischer M, et al. A phase I, open-label, dose escalation study of afatinib, in a 3-week-on\/1-week-off schedule in patients with advanced solid tumors. Investig New Drugs. 2013;31:399\u2013408.","journal-title":"Investig New Drugs"},{"key":"3398_CR38","doi-asserted-by":"publisher","first-page":"113801","DOI":"10.1016\/j.isci.2025.113801","volume":"28","author":"MA Huismans","year":"2025","unstructured":"Huismans MA, Smabers LP, Brunner SR, van Hoeck A, Kaa D, van de, Franken IA, et al. Impact of treatment history on drug resistance of metastatic colorectal cancer organoids. iScience. 2025;28:113801.","journal-title":"iScience"}],"updated-by":[{"DOI":"10.1038\/s41416-026-03616-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000}}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03398-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03398-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03398-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:36:22Z","timestamp":1790400982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03398-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,6,20]]}},"alternative-id":["3398"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03398-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In the Abstract, RESULTS section, the article originally stated \u201c\u2026with 9 (27%) achieving stable disease\u201c; the correct statement is: \u201c\u2026with 8 (24%) achieving stable disease\u201d. In the Results section, the article originally stated \u201c\u2026nine patients had stable disease at first evaluation (27%)\u201d; the correct statement is: \u201c\u2026eight patients had stable disease at first evaluation (24%)\u201d. In the Discussion section, the article originally stated: \u201c\u2026although 23% achieved stable disease with three maintaining stability beyond three months\u201d; the correct statement is: \u201c\u2026although 20% achieved stable disease with three maintaining stability beyond three months\u201d.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41416-026-03616-6","URL":"https:\/\/doi.org\/10.1038\/s41416-026-03616-6","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no known conflict of interests. The following interests may be considered as potential competing interests. Sjoerd Elias: grants\/contracts\/advisory role: Merck. Filip de Vos: advisory role: MyTomorrows; grants\/contracts: Novartis, Servier, STOPBraintumors.org; leadership roles: Dutch Rare Cancer Platform, European Association for Neuro-Oncology Education committee, European Organisation for Research and Treatment of Cancer; committee member: Dutch Society Neuro-Oncology Guideline committee. Frans Opdam: Participating in DSMB: IOMX. Leading PI: Astra Zeneca, Boehringer ingelheim, Crescendo, Cytovation, GSK, Incyte, Int1B3, Lilly, Merus, Pierre Fabre, Relay, RevMed, Roche, Taiho. Miriam Koopman: grants\/contracts\/advisory roles with: Amgen, Bayer, BMS, IqVIA, Merck, MSD, Nordic Farma, Novartis, Personal Genome Diagnostics, Pierre Fabre, Roche, Sanofi, Servier, and Sirtex. Jeanine Roodhart: grants\/contracts\/advisory roles with: AMGEN, BMS, Cleara Biotech, GSK, HUB Organoids, Incyte, Pfizer, Pierre Fabre, Servier, and Xilis; Board Membership: Foundation Hubrecht Organoid Biobank. All grants were unrelated to the study and paid to individual\u2019s institutions.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was registered under EudraCT identifier 2019-004987-23 and conducted in the University Medical Centre Utrecht in Utrecht, the Netherlands. The study protocol and all amendments were reviewed and accepted by the associated Medical Research Ethics Committee and the Dutch competent authority. The study was conducted in full conformance with the principles of the declaration of Helsinki, guidelines for Good Clinical Practice and local legislation. Written informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}